GlassScriptPhysician profile
Byron L Varnado
NPI 1962405357
$1,303.53
in general payments reported to CMS, 2019-2025
22 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $158 · 2021: $57.00 · 2022: $34.91 · 2023: $98.18 · 2024: $119 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.04 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $296.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $216.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $127.82 | 2019 | |
| Amgen INC. | $111.05 | 2019-2020 | |
| Abbvie INC. | $91.02 | 2023-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.51 | 2019-2025 | Jardiance |
| Welch Allyn | $57.00 | 2021 | |
| Lundbeck LLC | $51.55 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $41.77 | 2019-2020 | |
| Lilly USA, LLC | $33.96 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.63 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $20.92 | 2023 | Ingrezza |
| Astellas Pharma US INC | $20.80 | 2024 | Veozah |
| Collegium Pharmaceutical, INC. | $20.00 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $19.25 | 2025 | The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $16.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.34 | 2019 | |
| Radius Health, INC. | $14.32 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Varnado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.